OPIS

OPIS is a Global Full-Service clinical CRO providing premium clinical trial management for multi-country trials. In addition, to phase I-IV drug-related trials, OPIS also manages pre-and post-marketing clinical investigations for medical/diagnostic devices and nutraceutical/food supplement studies. Founded in 1998, the company counts 14 offices around the world (Italy, Spain, France, Germany, UK, Belgium, Sweden, Poland, Switzerland, Netherlands, Taiwan, Australia, Korea, and the US).

Panion & BF Biotech Inc.

後補

Pen-Ling Biotechnology Co.,Ltd.

Plateletsomes (PRPII） is more effective than PRP. Labortory data showed that PRPII has 4 times more growth factors and ILIRa than PRP. There is a significant effect on fracture healing, dry eye, skin defect, and infertility.

PharmaEssentia Corp.

In the field of protein drug design, the process of pegylation of the therapeutic protein preserves its biologic activity by targeting the PEG polymer (polyethylene glycol) at a specific and a defined region on the protein. PharmaEssentia’s pegylation technology platform is designed to increase the protein drug’s efficacy by prolonging its circulation in the blood stream. Utilizing its innovative 40K PEG and its novel pegylation technology platform by combining protein engineering and PEG-related chemistry, PharmaEssentia creates novel product- Ropeginterferon alfa-2b for better disease treatment. Compared with similar drugs on the market, the long-acting, mono-pegylated proline interferon with improved pharmacokinetic properties allowing once every two weeks administration offering improved tolerability and convenience. The marketing authorization for Ropeginterferon alfa-2b for treatment of Polycythemia Vera (PV) is granted by EMA in February 2019, Taiwan in May 2020 and FDA in November 2021.

PharmiGENE, Inc.

PharmiGene Inc. focuses on pharmacogenetics, providing genetic test of personalized medicine to help people finding their optimal medecines and avoiding side effects.

《Patented PGx detection reagent (IVD)》
We holds patents of carbamazepine, allopurinol and Warfarin gene testing. We developed these tests to IVD and having multinational license, selling to China, US, Europe, South Korea, SEA.

《IVD CDMO service》
Our manufacturing plant is ISO 13485 and GMP certified. In addition, we also use relevant professional experience to provide IVD CDMO services. We comply with globally consistent standards and flexible production volume without long waiting. We can be your production partner in Asia.

《LDTs Service-pharmacogenetics test》
PharmiGene provides common medications gene testing, cardiovascular disease drug gene testing, clopidogrel drug gene testing and Baktar gene testing.

《Solutions》
PharmiGENE is the distributor of various world-known biotech equipment and reagents. These products spread across the whole spectrum of NGS experiment workflow, with application in cancer research, neuroscience, immunology, etc.
We provide professional consultations, expertise experiences, and versatile solutions. Our role is to boost the research capability in every research institute, medical center, and university. Contact us to unveil more research potential.
Distributing brands include 10x genomics, Bionano Genomics, Immudex, S2 Genomics, and Varsome.

Prisma Biotech

The unprecedented resolution gained with the Tapestri Solution for Solid Tumor Research empowers cancer researchers to ask the questions they could never ask before. From deciphering the order of mutation acquisition to accurately measuring genomics changes like SNVs and CNVs across thousands of individual cells, Tapestri is bringing a new standard of clarity to solid tumor research.

Prorich Medical Corporation

Prorich® COVID-19 Dry One-Step RT-PCR Kit
Prorich® COVID-19 Influenza A/B Multiplex Dry One-Step RT-PCR Kit
Prorich® COVID-19 All-In-One Test Kit
Prorich® Release Buffer with Swabs Kit
Prorich® Coagulation Analyzer

Provitaebio Bio

"ProScreen" gene testing to test the patient's genetic data, and provide the doctor as a reference basis for selection of target drug. "ProScreen" uses next-generation sequencing genetic screening technology to detect 523 genetic data related to immune check point drugs and target drugs for tumor tissues and blood samples at a time. The detection range is wider, more comprehensive, and further assist physicians to choose accurate and suitable medication for patients.

Quark Biosciences, Inc.

Quark Biosciences has developed an innovative diagnostics platform for clinical testing, NextAmp™ Analysis System, which is built for ease of use, speed and decentralized distribution, while still being capable of performing highly complex multi-biomarker analysis. Coupled with our comprehensive genomic database, we are developing first-in-class tests in the precision oncology and fertility treatment markets.

Rock Biomedical, Inc.

Founded in 2021, Rock BioMedical, Inc. (Rock Bio) is a biopharmaceutical company seeking to combine both active immunization (eg vaccines) and passive immunization (eg antibodies) for the eradication of diseases based on our proprietary Glyco-engineered Universal Vaccine platform. The initial focus will be on the development of next generation COVID vaccine featuring the unique property of our glycan-depleted SARS-CoV-2 spike protein (SMG) to induce broad protection against immune evading variants. Built upon the same technology platform, the company’s pipeline also includes novel therapeutic antibody and universal flu vaccine candidates that together will revolutionize the way such common respiratory tract infection can be managed in the future. The company is founded upon a set of core technologies licensed from Academia Sinica. It has an R&D base located in National Biotechnology Research Park in Nangang Taipei and a subsidiary in Boston Massachusetts USA to manage its global CRO activities for clinical development and international partnership.